The Efficacy and Safety of Adjuvant Immunotherapy After Pathological Complete Response Following Neoadjuvant Chemoimmunotherapy in Patients with Resectable NSCLC
This is a prospective, observational, multicenter real-world study aiming to investigate the efficacy and safety of NSCLC patients with or without adjuvant immunotherapy who have achieved pathologic complete remission after neoadjuvant immunotherapy.
Resectable/Potentially Resectable NSCLC
DRUG: Immunotherapy
DFS (Disease-Free Survival), Evaluated by investigator based on RECIST1.1, Approximately 3 years
3-year DFS (disease-free survival) rate, Evaluated by investigator based on RECIST1.1, Approximately 3 years|OS (Overall Survival), Evaluated by investigator based on RECIST1.1, Approximately 3 years|Recurrence and Metastasis Pattern, Approximately 3 years|AE (Adverse Event), An AE is any untoward medical occurrence in a patient or clinical investigation participant administered an investigational product. Safety and tolerance evaluated by incidence, severity and outcomes of AEs (according to NCICTCAE 5.0), Approximately 3 years
This is a prospective, observational, multicenter real-world study aiming to investigate the efficacy and safety of NSCLC patients with or without adjuvant immunotherapy who have achieved pathologic complete remission after neoadjuvant immunotherapy.